Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-arm, multicenter, phase II clinical study to evaluate the efficacy and safety of GLS-010 injection in the treatment of recurrent or refractory classical Hodgkin's lymphoma

Trial Profile

A single-arm, multicenter, phase II clinical study to evaluate the efficacy and safety of GLS-010 injection in the treatment of recurrent or refractory classical Hodgkin's lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zimberelimab (Primary)
  • Indications Hodgkin's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Guangzhou Gloria Biosciences
  • Most Recent Events

    • 31 May 2020 Preliminary results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 10 Mar 2020 According to a Ligand Pharmaceuticals media release, the company announced the filling of marketing authorization of zimberelimab in China, based on the data from this trial.
    • 04 Feb 2020 Planned End Date changed from 31 Aug 2021 to 11 Apr 2022.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top